Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6955463 | 0.78 | ALDH1A1 (0.35) | TSHRKIF11HSD17B10 | |
| SCHEMBL7137116 | 0.78 | ALDH1A1 (0.35) | TSHRKIF11HSD17B10 | |
| SCHEMBL11234738 | 0.78 | SIGMAR1 (0.36) | SIGMAR1EBPTSHRKIF11CNR2 | |
| SCHEMBL5879351 | 0.76 | KIF11 (0.38) | SIGMAR1TSHRKIF11CNR2CNR1 | |
| SCHEMBL5879368 | 0.75 | KIF11 (0.35) | SIGMAR1TSHRKIF11 | |
| SCHEMBL7266435 | 0.74 | EBP (0.53) | SIGMAR1EBP | |
| SCHEMBL8445608 | 0.73 | TSHR (0.40) | TSHRKIF11CASP1HSD17B10CNR2 | |
| SCHEMBL6986308 | 0.73 | TSHR (0.40) | TSHRKIF11 | |
| SCHEMBL8470869 | 0.70 | — | — | |
| SCHEMBL10372417 | 0.70 | TDP1 (0.40) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034056-B2 | Aryl and biaryl compounds having MCH modulatory activity | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-04-25 | — | — | US | disclosed |
| US-20030092715-A1 | Aryl and biaryl compounds having MCH modulatory activity | SCHERING CORPORATION | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092715-A1 | Aryl and biaryl compounds having MCH modulatory activity | MCHR1, MCHR2, MC3R | SIGMAR1 68/4885EBP 1214/4885TSHR 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.